Showing results (1-10 of 731) with videos related to
Sort By:
Pageof 74
Immunotherapy|December 22, 2016
Prospects to improve chimeric antigen receptor T-cell therapy for solid tumorsChuan Jin, Di Yu, Magnus EssandNature Biomedical Engineering|April 5, 2022
CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancersChuan Jin, Jing Ma, Mohanraj Ramachandran, et al.Journal of Immunology (Baltimore, Md. : 1950)|July 23, 2014
Vector-encoded Helicobacter pylori neutrophil-activating protein promotes maturation of dendritic cells with Th1 polarization and improved migrationMohanraj Ramachandran, Chuan Jin, Di Yu, et al.EMBO Molecular Medicine|May 19, 2016
Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transferChuan Jin, Grammatiki Fotaki, Mohanraj Ramachandran, et al.Human Gene Therapy|July 30, 2013
Tat-PTD-modified oncolytic adenovirus driven by the SCG3 promoter and ASH1 enhancer for neuroblastoma therapyChuan Jin, Di Yu, Matko Čančer, et al.Molecular Therapy. Methods & Clinical Development|May 28, 2015
Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factorsChuan Jin, Di Yu, Victoria Hillerdal, et al.Journal of Virology|September 30, 2011
Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumorsDi Yu, Chuan Jin, Justyna Leja, et al.Molecular Therapy. Nucleic Acids|November 25, 2024
Targeting ZC3H11A elicits immunogenic cancer cell death through augmentation of antigen presentation and interferon responseArwa Ali, Paola Contreras, Mahmoud Darweesh, et al.Cell Death & Disease|January 24, 2020
Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancerJing Ma, Mohanraj Ramachandran, Chuan Jin, et al.Oncoimmunology|February 6, 2018
Pro-inflammatory allogeneic DCs promote activation of bystander immune cells and thereby license antigen-specific T-cell responsesGrammatiki Fotaki, Chuan Jin, Mohanraj Ramachandran, et al.Pageof 74